A global leader in gene therapy
Having originated the first approved gene therapy in 2012, uniQure is a leading pioneer in the field. By leveraging their modular and validated technology platform, uniQure is rapidly advancing a pipeline of AAV-based gene therapies to treat patients with hemophilia, Huntington’s disease, and other severe genetic diseases.
Challenges
| Difficulty tracking experiments with paper documentation | Paper-based workflows made it difficult to track results and streamline experiment execution. |
|---|---|
| Sharing data and collaborating across international sites | As an international company with worksites in Amsterdam and Lexington, MA, uniQure found it challenging to share data and collaborate across research sites. |
| Difficulty assessing experiment quality | A lack of standardized Notebook templates led to nonstandard experimental workflows and impeded quality control. |
Outcomes
| End-to-end tracking for gene therapy workflows | Benchling automatically creates a complete history of every experiment. Scientists can track from vectors, to tissue samples, to viral batches and experimental results. |
|---|---|
| International collaboration — even while working remotely | Having a digital system enables internationally distributed researchers to collaborate and discover data much more easily – even when working from home due to the COVID-19 pandemic. |
| Improved efficiency and enthusiastic adoption | Benchling Notebook templates massively improve scientist efficiency. 100% of the scientists licensed to use Benchling use the Notebook every day. |
